帕米帕利联合节拍替莫唑胺治疗复发性IDH突变胶质瘤的I/II期研究
这项多中心I/II期及机会窗研究评估了PARP抑制剂帕米帕利联合节拍低剂量替莫唑胺在复发性IDH突变胶质瘤患者中的安全性、耐受性、药代动力学和疗效。确定II期剂量为帕米帕利60mg每日两次联合替莫唑胺20mg每日一次,药物在强化和非强化肿瘤中均达到足够药理活性浓度,但客观影像学缓解率有限,且累积血液学毒性显著影响长期耐受性。
要点
- 帕米帕利60mg每日两次联合替莫唑胺20mg每日一次被确定为II期推荐剂量。
- 药物在强化和非强化肿瘤中未结合型肿瘤/血浆比分别为0.98和0.92。
- 客观缓解率低:A组0/15,B组1/24达到中心确认的部分缓解。
核心结论
- 帕米帕利在强化和非强化肿瘤中均达到足够药理活性浓度。
- 帕米帕利联合替莫唑胺在复发性IDH突变胶质瘤中未产生有意义的客观缓解率。
- 累积血液学毒性显著,影响长期耐受性。
研究设计与样本
- 多中心I/II期及机会窗研究,纳入66例复发性IDH突变胶质瘤患者。
- I期确定最大耐受剂量后,II期入组两个队列:A组(多线既往化疗)和B组(单线既往方案),采用两阶段设计。
- 探索性队列评估4级IDH突变患者及帕米帕利瘤内药代动力学。
- 主要终点为按RANO标准的客观影像学缓解率。
主要发现
- A组0/15、B组1/24患者达到中心确认的部分缓解。
- A组中位无进展生存期5.9个月(95%CI,1.2-14.8个月),B组9.7个月(95%CI,5.7-21.7个月)。
- 3级及以上贫血和中性粒细胞减少分别影响24%和33%的患者。
关键数值与推荐
- II期推荐剂量:帕米帕利60mg每日两次联合替莫唑胺20mg每日一次。
- 非强化肿瘤中帕米帕利未结合型肿瘤/血浆比为0.92,强化肿瘤中为0.98。
临床怎么用
- 帕米帕利联合节拍替莫唑胺在复发性IDH突变胶质瘤中缓解率有限,需权衡血液学毒性。
- 部分患者可获得延长无进展生存,但累积血液学毒性影响长期治疗耐受性。
局限性
- 样本量有限(66例),II期采用两阶段设计。
- 累积血液学毒性显著,33.3%患者因非肿瘤进展原因停止治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical studies demonstrate activity of poly(adenosine 5'-diphosphate-ribose) polymerase (PARP) inhibitors in isocitrate dehydrogenase (IDH) mutant gliomas. We investigated safety, tolerability, pharmacokinetics, and efficacy of the PARP inhibitor pamiparib in conjunction with metronomic low-dose temozolomide in patients with recurrent IDH mutant (IDHmt) gliomas in a multicenter Phase I/II/window of opportunity study. METHODS: Patients received pamiparib in conjunction with daily temozolomide. Following Phase I determination of maximum tolerated dose (MTD), we enrolled 2 patient cohorts (Arm A, multiple prior chemotherapy regimens; Arm B, single prior regimen) in a 2-stage design. Exploratory cohorts examined grade 4 IDHmt patients and intratumoral pharmacokinetics of pamiparib. The primary endpoint was objective radiographic response (ORR) by RANO criteria. RESULTS: Sixty-six subjects were enrolled. We established pamiparib 60 mg twice daily with temozolomide 20 mg daily as the phase II dose. In non-enhancing and enhancing tumor, pamiparib exhibited an unbound tumor/plasma ratio of 0.92 and 0.98, respectively. 0/15 Arm A and 1/24 Arm B patients achieved a centrally confirmed partial response. Median progression-free survival for Arm A was 5.9 months (95% CI, 1.2-14.8 months), and for Arm B was 9.7 months (95% CI, 5.7-21.7 months). Grade 3+ anemia and neutropenia affected 24% and 33% of patients, respectively. Twenty-two of 66 patients (33.3%) discontinued study treatment for reasons other than tumor progression. CONCLUSIONS: Pamiparib appeared to achieve sufficient pharmacologically active concentrations in both enhancing and non-enhancing tumors. While some patients achieved prolonged progression-free survival, combination with temozolomide did not produce a meaningful ORR in IDHmt recurrent gliomas. Cumulative hematologic toxicity was substantial and impacted long-term tolerability.
引用
- Schiff D, Ye X, Li J, et al. Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas. Neuro Oncol. 2026. PMID: 41099363. doi:10.1093/neuonc/noaf246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。